What drove the RHY.AX stock jump today?

The RHY.AX stock rise was driven by heavy volume at **3,593,802** shares and strong intraday momentum. No single public ASX release explained the move at close; traders linked the surge to event‑driven buying and technical break above the 50‑day average

What is Meyka AI's grading for RHY.AX stock?

Meyka AI rates RHY.AX **59/100 (Grade C+, Suggestion: HOLD)**. The grade blends benchmark and sector comparisons, financial growth, key metrics and model forecasts. This is informational and not investment advice

What price targets and forecasts exist for RHY.AX stock?

Meyka AI's forecast model projects **A$0.150** (monthly), **A$0.100** (quarterly) and **A$0.07239** (yearly). Short technical resistance sits at **A$0.280**, support at **A$0.205**. Forecasts are model‑based and not guarantees

Which catalysts could move RHY.AX stock next?

Key catalysts for RHY.AX stock are the earnings announcement on **20 Feb 2026**, clinical or commercial updates on ColoSTAT, partnership deals, and any capital‑raising news. Each can materially change liquidity and valuation

AU Stocks

RHY.AX Rhythm Biosciences (ASX) +40.00% 06 Feb 2026: Volume spike, model warns

ByHuzaifa Zahoor February 6, 2026February 6, 2026

The RHY.AX stock move stunned traders today as Rhythm Biosciences (ASX) closed at A$0.245, up 40.00% on 3,593,802 shares traded. The jump pushed price above the 50‑day average (A$0.1224) and came with a clear volume surge, signalling active repositioning. Investors should weigh the rally against weak fundamentals, listed metrics and Meyka AI’s model forecasts before repositioning in the healthcare diagnostics name